FDA Consider Regulation of CME Programs Paid for By Drug Companies; Goal To Limit Promotion
In Brief: NCI Encourages New Grants In For Cancer Sites In Forthcoming PA, Broder Informs Grantees
Wyden Asks Healy To Clarify CRADA Pricing Clause
Lung Cancer Deaths Level Off In White Men, NCI Study Says
Trending Stories
- Is it time to re-assess the practice and practicality of screening colonoscopy?
Modeling data, ACS guideline support greater use of noninvasive tests to ease system strain, help save lives - The Directors: Two Gulf Coast cancer center directors on why NCI designation matters—and why they want it
Lucio Miele and Raghu Kalluri: Science and technology have changed what an aspiring cancer center must accomplish - FDA advisory committee votes in favor of Galleri approval, but calls for removal of “early” detection claims
Clinical benefit will not be considered for approval, FDA says - Trump weighs—and abandons—an executive order that would give OMB veto power over NIH grants
- From “default dead” to living the future of cancer care
As founding CEO of GitLab, I went “founder mode” on my osteosarcoma - The Galleri MCD vote: What FDA asked its advisors to ignore









